Top Stories in the Financial Times: NHS, Defence Budget, H2O Asset Management, and Tech Hiring

The Financial Times' top stories include NHS's deployment of a gene therapy drug, the Ministry of Defence seeking budget cuts, H2O Asset Management agreeing to compensate investors, and the UK's intention to limit overseas hiring in tech and engineering sectors.

In a significant move, Britain's NHS is set to roll out a new gene therapy from Vertex Pharmaceuticals and CRISPR Therapeutics, designed to treat the rare blood disorder beta thalassemia.

The Ministry of Defence has asked major industry suppliers to pinpoint immediate budget cut opportunities, reflecting ongoing fiscal constraints.

Meanwhile, H2O Asset Management has agreed to pay 250 million euros to investors affected by serious breaches discovered by the FCA. The firm will also shut down its UK operations.

In another development, the UK government is signaling its intent to curb overseas hiring in the technology and engineering sectors, seeking a review of dependence on skilled worker visas.

(With inputs from agencies.)